Impaired Humoral Immunogenicity of SARS-CoV-2 Vaccination in Patients With Rheumatoid Arthritis

J Rheumatol. 2022 Jul;49(7):855-858. doi: 10.3899/jrheum.211270. Epub 2022 Feb 1.

Authors

Camille Le Moine¹, Muhammad Shahnawaz Soyfoo², Leila Mekkaoui³, Hafid Dahma³, Laure Tant²

Affiliations

¹ Department of Rheumatology, Hôpital Erasme, Université Libre de Bruxelles; camille.le.moine@erasme.ulb.ac.be.
² Department of Rheumatology, Hôpital Erasme, Université Libre de Bruxelles.
³ Microbiology Department, Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel (LHUB-ULB), Université Libre de Bruxelles, Brussels, Belgium.

PMID: 35105706
DOI: 10.3899/jrheum.211270

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Viral
Arthritis, Rheumatoid* / drug therapy
COVID-19 Vaccines
COVID-19* / prevention & control
Humans
Immunity, Humoral
Rituximab
SARS-CoV-2
Vaccination

Substances

Antibodies, Viral
COVID-19 Vaccines
Rituximab